Insights On Pharma Logistics

  1. Friendshoring: A Strategic Shift In Pharma Supply Chains 4/11/2025

    To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

  2. Strengthening Europe's Advanced Therapy Supply Chain 3/25/2025

    Ensure the seamless development and commercialization of your ATMPs in Europe with integrated supply chain solutions that optimize logistics, biostorage, and regulatory compliance.

  3. The Gateway To Europe: How The Stevenage Supply Chain Hub Supports ATMP Development 3/25/2025

    Ensure seamless access to European clinical trials and markets with GMP-compliant logistics, regulatory support, and risk mitigation to protect the integrity of your advanced therapies.

  4. How Our Recent Innovative Solutions Meet Today's Supply Chain Challenges 3/25/2025

    When advanced therapy organizations place innovation at the heart of their strategy for overcoming supply chain challenges, they ultimately prioritize the most important stakeholder — the waiting patient.

  5. Supply-Chain Statistics And Realistic Outsourcing Options 3/12/2025

    Kishore Hotha, President, Dr. Hotha’s Life Sciences, provides some telling stats that should inform outsourcing decision-making in the coming months… and perhaps years.

  6. Remind Me: Why Are We At Biotech War With China? 3/12/2025

    It’s hard to focus on the issues that precipitated the challenges and proscribed solutions to so much of our supply chain being in China. IP was (and should be) at the center of the discussion.

  7. Good 'Supplier Hygiene' Before And After COVID And The BIOSECURE Act 3/12/2025

    Can you recall the fundamentals of outsourcing development and manufacturing five or 10 years ago, if you were in the industry then? Our panel can, and it’s instructive to take the trip back in time.

  8. Smaller Biotechs Take Bigger Hits 3/12/2025

    Our panel of experienced biopharma executives explain the different effects on trade wars or supply-chain disruptions with Big Pharma and smaller drug development organizations.

  9. Can We Actually Decouple US-China Supply-Chain Integration? 3/12/2025

    The realities in 2024 suggest the answer is no, and our panel of speakers detail why that is the right answer.

  10. The Costs Of Disengagement From China 3/12/2025

    If we ever did implement (suffer through?) some rather large-scale “disengagement” between the U.S. and China in the biopharma industry realm, what costs would we incur?